Johnson & Johnson (JNJ): FY25 Q2 earnings call, Jul 16, 2025
No Kalshi or Polymarket word markets were listed for Johnson & Johnson’s Jul 16, 2025 earnings call (FY25 Q2). The transcript is searchable below (quotes of at most 25 words).
UpdatedTranscript
quotes of at most 25 wordsSpeaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.
5 matches for “Carvykti”; 5 quoted, at least 25 words apart.
…Our performance was driven by double-digit growth across 3 brands including DARZALEX, CARVYKTI, [indiscernible] as well as [indiscernible] and in medtech, we delivered 6.1% operational…
…new 5-year data showing a single treatment of our CAR T therapy CARVYKTI has the potential to deliver long-term remission. We also presented the first…
…to 8 points in the frontline setting as well as market growth. CARVYKTI achieved sales of $439 million with growth of over 100%. And driven…
…drivers there. So first, in oncology, DARZALEX continues to perform very well. CARVYKTI performed well, [ ERLEADA. ] And we're really pleased with the launch…
…at multiple myeloma with DARZALEX and a lot of continued growth opportunity CARVYKTI also a $5 billion-plus brand. We've got TECVAYLI and TALVEY. We may…
Agents: this page as TSV at /api/v1/appearances/johnson-and-johnson:2025-07-16:earnings_call · words: /api/v1/brief?appearance=johnson-and-johnson:2025-07-16:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP